Agesen, Rikke Mette http://orcid.org/0000-0002-7649-7928
Alibegovic, Amra Ciric
Andersen, Henrik Ullits
Beck-Nielsen, Henning
Gustenhoff, Peter
Hansen, Troels Krarup
Hedetoft, Christoffer
Jensen, Tonny
Juhl, Claus Bogh
Lerche, Susanne Søgaard
Nørgaard, Kirsten
Parving, Hans-Henrik
Tarnow, Lise
Thorsteinsson, Birger
Pedersen-Bjergaard, Ulrik
Article History
Received: 10 April 2019
Accepted: 15 July 2019
First Online: 23 July 2019
Ethics approval and consent to participate
: Prior to any protocol-related procedures written informed consent is obtained.The study is performed in accordance with the Helsinki Declaration and the ICH GCP guide-lines after approval by the Committee System on Biomedical Research Ethics (#H-3-2014-101) and the Danish Health and Medicines Authority (#2014071615).
: Not applicable.
: RMA, ACA, HBN, TKH, CH, TJ, CBJ, SSL, HHP, LT and BT have no competing financial interests. HUA owns stocks in Novo Nordisk. HUA is on advisory boards for Novo Nordisk, Abbott and Astra Zeneca and has received a lecture fee from Nordic Infucare. PG has served on advisory boards for Astra Zeneca, Sanofi Aventis, Novo Nordisk, Boehringer Ingelheim and Abbott Laboratories. KN serves as advisor to Medtronic, Abbott and Novo Nordisk. KN has received fees for speaking from Medtronic, Roche Diabetes Care, Rubin Medical, Sanofi, Novo Nordisk, Zealand Pharma and Bayer. UPB has served on advisory boards for AstraZeneca/Bristol Myers Squibb and Novo Nordisk and has received lecture fee from Astra Seneca/Bristol Myers Squibb, Sanofi Aventis and Novo Nordisk. The authors declare no other conflict of interest.